FDA Set To Prioritize Review Of Bristol-Myers Squibb Cancer Cell Therapy Critical To Celgene Merger

Off the back of its $74 billion acquisition of Celgene, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted its biologics license application (BLA) for its CAR-T treatment priority review. This means a decision will come as soon as August 17, 2020, which is four months earlier than it would have under the standard review process. Similar to other CAR-T therapies, liso-cel involves taking immune cells and manipulating them so they target lymphoma cells expressing proteins consistent with blood cancer, like CD19...